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Background: Management of community-acquired pneumonia (CAP) places a considerable burden on hospital
resources. REACH was a retrospective, observational study (NCT01293435) involving adults ≥18 years old hospitalized
with CAP and requiring in-hospital treatment with intravenous antibiotics conducted to collect data on current clinical
management patterns and resource use for CAP in hospitals in ten European countries.
Methods: Data were collected via electronic Case Report Forms detailing patient and disease characteristics,
microbiological diagnosis, treatments before and during hospitalization, clinical outcomes and health resource
consumption.
Results: Patients with initial antibiotic treatment modification (n = 589; 28.9%) had a longer mean hospital stay than
those without (16.1 [SD: 13.1; median 12.0] versus 11.1 [SD: 8.9; median: 9.0] days) and higher ICU admission rate (18.0%
versus 11.9%). Septic shock (6.8% versus 3.0%), mechanical ventilation (22.2% versus 9.7%), blood pressure support (fluid
resuscitation: 19.4% versus 11.4%), parenteral nutrition (6.5% versus 3.9%) and renal replacement therapy (4.2% versus
1.4%) were all more common in patients with treatment modification than in those without. Hospital stay was longer
in patients with comorbidities than in those without (mean 13.3 [SD: 11.1; median: 10.0] versus 10.0 [SD: 7.5; median:
8.0] days).
Conclusions: Initial antibiotic treatment modification in patients with CAP is common and is associated with
considerable additional resource use. Reassessment of optimal management paradigms for patients hospitalized with
CAP may be warranted.
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In Europe, the total annual costs of pneumonia exceed
€10 billion [1]. Community-acquired pneumonia (CAP),
with an annual incidence rate of between 1.6 and 10.8
cases per 1,000 adults per year [2], makes a considerable
contribution to this figure. In Spain, there are reported
to be 51,000 hospitalizations for CAP per year (a rate of
1.6 per 1,000 population) [3], while median total costs
per patient for hospitalized CAP patients in Germany
are estimated at US$1,333 (2003 costs) [2].* Correspondence: Helmut.ostermann@med.uni-muenchen.de
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distribution, and reproduction in any mediumStudies in the USA show that the main component of
the economic burden of CAP is inpatient treatment
costs, which account for around 90% of the total cost
[4]. Furthermore, of these costs, hospital stay and anti-
biotic treatment are the largest contributors [2,5]. These
components are also interlinked, in that length of stay is
influenced by choice of initial-line antibiotic; inappropri-
ate therapy results in additional costs [6]. While these
data are valuable, there are no comparable or more com-
prehensive data on the economic burden of CAP across
Europe as a whole and the contribution of hospital re-
source use to this burden.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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Clinical Management of Patients With Moderate-to-
Severe complicated skin and skin structure infections
[cSSTI] or CAP in the Hospital Setting) was conducted
to address the gaps in the available data. The main ob-
jectives of the study, which are reported in the primary
publication for this study [7], were to collect detailed
background data on the population of patients hospital-
ized with CAP in Europe, to provide a summary of clinical
practice decisions in these patients and to understand the
impact of these decisions in terms of rates of initial anti-
biotic treatment modification and mortality. A key sec-
ondary objective was to gather data on resource use in
patients hospitalized with CAP and the associated costs to
understand the economic impact of the disease. These
health economic data are reported here, including an as-
sessment of inter-country differences across the region.
The complicated skin and soft tissue infections data were
considered and are reported separately.
Methods
Overview
REACH was a multinational, multicentre, observational,
retrospective cohort study of patients hospitalized with
CAP and cSSTI (NCT01293435; cSSTI data are analysed
and reported separately). Patients were enrolled from 128
sites in ten participating countries (Belgium, France,
Germany, Greece, Italy, the Netherlands, Portugal, Spain,
Turkey and the UK). All included patients were hospital-
ized between March 2010 and February 2011. Study de-
sign and patient inclusion and exclusion criteria are
summarised in the companion paper presenting the re-
sults of the primary objectives [7]. Study variables were
collected via an electronic Case Report Form. In brief, the
study collected data about patient demographics, disease
characteristics and diagnosis, management (with particu-
lar focus on antibiotics received), clinical outcomes
(including initial treatment modification rate) and use of
resources. The study was performed according to Good
Clinical Practice and the Declaration of Helsinki. All local
ethics committees approved the study protocol (a list of
all participating sites can be found in Additional file 1).
Local legislation relating to written informed consent for
non-interventional studies was followed in each country;
in Germany and Portugal, where this information is
mandatory, written informed consent was collected.
Statistical methods and data interpretation
This was a retrospective non-interventional study, using
a descriptive analysis approach to assess clinical manage-
ment, clinical outcomes and healthcare resource use. All
calculations and summaries were produced using SAS
Version 9.2. Only descriptive (no analytical) data are
provided.Hospitalization costs for each of the countries involved
were determined using estimated unit cost values for pri-
mary and secondary healthcare services derived from the
World Health Organization (WHO) CHOosing Interven-
tions that are Cost-Effective (CHOICE) project (http://www.
who.int/choice/country/country_specific/en/index.html) [8].
The values are averages of unit costs for the country, based
on specific assumptions regarding the organisation of health
services and operational capacity.
‘Initial antibiotic treatment modification’ was defined as
a change in initial antibiotic treatment due to insufficient
response, adverse reaction, interaction with other drugs,
non-suitability of the initial antibiotic based on the results
of microbiological tests or changes to or addition of new
agents in a subsequent line, alone or in combination. Co-
morbidities were defined as relevant medical conditions at
hospitalization. Investigators could select from a list of co-
morbidities outlined in the companion manuscript [7], or
include other conditions based on their own medical
criteria. Recurrences were defined as patients who were
hospitalized again (due to CAP), after initial discharge.
Immunosuppressed/immunocompromised patients were
patients who were on haemodialysis or chemotherapy,
with neutropenia, stem cell transplantation, HIV/AIDS or
iatrogenic immunosuppression (patients on biological
therapy) or corticoids (15 mg/day for ≥ 14 days, or equiva-




The analysis population included 2,039 patients. The
majority of patients (78.8%; n = 1,607) had CAP only (as
defined by residence in a private house or apartment
prior to admission) while 12.0% (n = 245) of patients had
healthcare-associated pneumonia (HCAP; defined as pa-
tients with residence in a nursing home, or receiving
home care through a healthcare agency, or admitted to
hospital in the 3 months prior to index admission, or
undergoing haemodialysis, or receiving chemotherapy
for active cancer). A detailed breakdown of information
on the study population is provided in the companion
paper [7].
Clinical outcomes
Clinical outcomes data for the full analysis population
are given in the primary publication [7]. Initial treatment
modification occurred in 28.9% of patients (n = 589).
The most common reasons for initial antibiotic treat-
ment modification were insufficient response to treatment
(12.0%) and adverse events (2%). The mean time to treat-
ment modification in the total population was 5.0 days
(standard deviation [SD]: 3.8; median: 4.0; n = 760). The
mean time to clinical stability was 5.6 days (SD: 5.1;
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(n = 147). In 5.1% of patients, streamlining of therapy, de-
fined as de-escalation to narrower spectrum antibiotic in
response to patient improvement or confirmed microbio-
logical diagnosis, was undertaken; this was not counted as
initial antibiotic treatment modification.
Clinical outcomes data by country are shown in Table 1.
Particularly high initial antibiotic treatment modification
rates were observed in the UK (37.7%; n = 43/114) and in
Belgium (35.6%; n = 68/191), while low initial antibiotic
treatment modification rates were observed in France
(15.6%; n = 57/366) and Greece (21.9%; n = 47/215).Hospital stay and resource use
Hospital stay and resource use for the full analysis popu-
lation (N = 2,039) and by disease characteristics at base-
line are shown in Table 2. The mean length of stay in
hospital was 12.6 days (SD: 10.6; median: 10.0), with
13.6% of patients admitted to the intensive care unit
(ICU), where they stayed for a mean of 9.5 days (SD: 11.7;
median: 5.0). The reason for admission was not given.
Similar percentages of patients required fluid resuscitation
and mechanical ventilation, and mechanical ventilation
was invasive in approximately half of the ventilated pa-
tients (the remainder receiving non-invasive mechanical
ventilation). Acute renal failure occurred in 2.3% of pa-
tients; it is unknown whether these occurrences were
treatment-related.
Resource use was generally greater in patients with















Belgium 191 (9.4) 68 (35.6) 23 (12.0) 6.0 (n = 135)
France 366 (17.9) 57 (15.6) 19 (5.2) 4.4 (n = 277)
Germany 50 (2.5) 18 (36.0) 0 5.9 (n = 35)
Greece 215 (10.5) 47 (21.9) 5 (2.3) 5.6 (n = 142)
Italy 300 (14.7) 100 (33.3) 3 (1.0) 6.3 (n = 263)
The
Netherlands
203 (10.0) 69 (34.0) 22 (10.8) 4.6 (n = 174)
Portugal 121 (5.9) 35 (28.9) 19 (15.7) 6.0 (n = 65)
Spain 279 (13.7) 96 (34.4) 19 (6.8) 6.0 (n = 247)
Turkey 200 (9.8) 56 (28.0) 17 (8.5) 7.2 (n = 171)
United
Kingdom
114 (5.6) 43 (37.7) 20 (17.5) 3.9 (n = 94)
Total
population
2,039 (100) 589 (28.9) 147 (7.2) 5.6 (n = 1,603)rates of fluid resuscitation, requirement for isolation and
parenteral nutrition, and duration of renal failure. How-
ever, the duration of ICU stay and duration of parenteral
nutrition were longer in patients with CAP than in those
with HCAP. Immunosuppressed/immunocompromised
patients with CAP had higher resource use compared
with CAP only and HCAP patients.
Analyses of hospital stay and resource use by clinical
outcomes are shown in Table 3. Patients requiring initial
antibiotic treatment modification (n = 589) had a longer
duration of hospital stay and were more likely to be ad-
mitted to the ICU, with a longer mean stay in the ICU
than those not requiring modification (n = 1,387). Blood
pressure support, mechanical ventilation, parenteral nu-
trition and renal replacement therapy were all also more
commonly required by these patients.
Patients with comorbidities (n = 1,598), which included
respiratory disease, diabetes and congestive heart dis-
ease, experienced longer stays in both hospital and ICU
than those without (n = 441). Patients with recurrent
CAP (n = 94) required more resources than patients with
a single infectious episode (n = 1,945), with a higher
length of hospital stay, rate of admission to ICU and
longer stay once admitted. The duration of parenteral
nutrition was more than doubled in patients with recur-
rent infection compared with those without.
As expected, patients with septic shock (n = 84) con-
sumed more resources compared with those without
(n = 1,955), with particularly high rates of blood pres-
sure support, mechanical ventilation, parenteral nutri-
tion and renal replacement therapy required in patients
with septic shock than in those without.
A comparison of resource use patterns by participating
country is shown in Table 4. The mean duration of hos-
pital stay varied between 9.6 days (SD: 6.4; median: 7.0)
in Greece and 15.0 days (SD: 13.2; median 11.0) in
Belgium. Wide variation between countries was observed
in the percentage of patients admitted to the ICU, with
Belgium having the highest rate (35.6%; n = 68/191) and
Italy the lowest (3.3%; n = 10/300). The mean duration of
ICU stay was similar in the majority of countries, with the
exception of Germany (22.5 days), although this finding
was based on a very small sample size (n = 6/50). Blood
pressure support in the form of fluid resuscitation was
considerably more common in the UK than in other
countries, while use of fluid resuscitation was highest in
the Netherlands and Greece.
Isolation of the patient was comparatively frequent in
the UK and France, while these countries, along with
Turkey, also had the highest proportions of patients
undergoing mechanical ventilation. On all other mea-
sures of resource use, either there were no meaningful
differences or the patient numbers involved were too
small to make any meaningful comparisons.




CAP (n = 1,607) HCAP (n = 245) Immunosuppressed/
Immunocompromised
(n = 72)
Total duration of hospitalization*,
days, mean (SD) [median]
12.6 (10.6) [10.0] (n = 1,978) 12.4 (10.4) [9.0] (n = 1,558) 13.2 (10.6) [11.0] (n = 235) 16.0 (13.3) [12.0] (n = 71)
Admitted to ICU at any time, n (%) 278 (13.6) 218 (13.6) 31 (12.7) 15 (20.8)
Time in ICU, days, mean (SD) [median] 9.5 (11.7) [5.0] (n = 244) 9.9 (12.3) [6.0] (n = 195) 5.2 (5.0) [2.5] (n = 28) 10.3 (12.0) [4.5] (n = 12)
Blood pressure support during
hospitalization, n (%)
Fluid resuscitation 251 (12.3) 178 (11.1) 43 (17.6) 15 (20.8)
Vasopressors 101 (5.0) 79 (4.9) 11 (4.5) 6 (8.3)
Invasive procedures 30 (1.5) 28 (1.7) 0 0
Isolation required, n (%) 154 (7.6) 99 (6.2) 23 (9.4) 19 (26.4)
Mechanical ventilation required during
hospitalization, n (%)
280 (13.7) 215 (13.4) 36 (14.7) 11 (15.3)
Invasive 139 (6.8) 110 (6.8) 13 (5.3) 8 (11.1)
Duration, days, mean (SD)
[median]
10.5 (12.7) [6.0] (n = 133) 10.4 (12.9) [6.0] (n = 126) N/A N/A
Non-invasive 166 (8.1) 125 (7.8) 26 (10.6) 4 (5.6)
Duration, days, mean (SD)
[median]
5.2 (4.5) [4.0] (n = 155) 5.0 (4.6) [4.0] (n = 144) N/A N/A
Parenteral nutrition, n (%) 94 (4.6) 60 (3.7) 26 (8.2) 6 (8.3)
Duration of parenteral nutrition, days,
mean (SD) [median]
9.1 (10.6) [5.0] (n = 88) 9.5 (11.4) [5.0] (n = 55) 6.6 (6.8) [5.0] (n = 19) 4.3 (2.5) [4.0] (n = 6)
Acute renal failure necessitating renal
replacement therapy, n (%)
46 (2.3) 38 (2.4) 5 (2.0) 1 (1.4)
Duration of renal failure, days,
mean (SD) [median]
6.5 (8.6) [3.0] (n = 37) 6.2 (7.1) [4.0] (n = 31) 11.5 (18.3) [2.5] (n = 4) 1.0 (−) [1.0] (n = 1)
Septic shock during hospitalization†, n (%) 84 (4.1) 61 (3.8) 9 (3.7) 8 (11.1)
Home-based care, n (%) 73 (3.6) 46 (2.9) 22 (9.0) 3 (4.2)
*Includes duration of all hospitalizations for patients with recurrences.
†Septic shock was defined as the presence of severe sepsis and one of the following conditions: a) systemic mean blood pressure of <60 mmHg (<80 mmHg if
previous hypertension) after 20 to 30 mL/kg starch or 40 to 60 mL/kg serum saline solution; b) pulmonary capillary wedge pressure between 12 and 20 mmHg and
need for dopamine of >5 mcg/kg/min; c) norepinephrine or epinephrine to maintain mean blood pressure at >60 mmHg (80 mmHg if previous hypertension).
CAP: community-acquired pneumonia; HCAP: healthcare-associated pneumonia; ICU: intensive care unit; SD: standard deviation.
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increased use of hospital resources
Patients with initial antibiotic treatment modification had
a longer mean hospital stay than those without (16.1; me-
dian: 12.0 versus 11.1; median: 9.0 days) (Table 3). The
unit costs per bed/day in either a secondary-level hospital
or a tertiary-level/teaching hospital for each of the partici-
pating countries are shown in Table 5. These data were
obtained from the WHO-CHOICE database [8] and show
the different costs of hospitalization in local currency for
each country (US$, Euro, Turkish Lira [TL] or GBP).
Discussion and conclusions
The REACH study has provided an opportunity to assess
real-world clinical management patterns of patients hos-
pitalized with CAP across Europe. Here we present dataon the level of resource use associated with this disease
in Europe as a whole and in each participating country
and consider the implications in terms of the economic
burden.
This study has confirmed that CAP is associated with
a high level of resource use. Previous studies show that
the key elements of the costs of CAP are hospital stay
and antibiotic use [2,4,5]. These findings are supported
by our study, where there was a considerable mean
length of stay in hospital of 12.6 days (median: 10.6). To
assess the impact of this length of stay in monetary
terms, we obtained data on the median costs of
hospitalization in each of the countries included (2007–
2008 data), using the WHO CHOICE project [8] (Table 5
and Figure 1). This project, which states costs in US$,
gives information on three different levels of hospital care:
Table 3 Hospital stay and resource use analysed by clinical outcomes

















Total duration of hospitalization,

















Admitted to ICU at any time, n (%) 106 (18.0) 172 (11.9) 219 (13.7) 59 (13.4) 19 (20.2) 177 (11.4) 69 (82.1) 209 (10.7)
















Blood pressure support during
hospitalization, n (%)
Fluid resuscitation 95 (16.1) 156 (10.8) 209 (13.1) 42 (9.5) 15 (16.0) 155 (10.0) 63 (75.0) 188 (9.6)
Vasopressors 46 (7.8) 55 (3.8) 77 (4.8) 24 (5.4) 5 (5.3) 42 (2.7) 71 (84.5) 30 (1.5)
Invasive procedures 13 (2.2) 17 (1.2) 22 (1.4) 8 (1.8) 2 (2.1) 13 (0.8) 12 (14.3) 18 (0.9)
Isolation required, n (%) 55 (9.3) 99 (6.8) 114 (7.1) 40 (9.1) 5 (5.3) 92 (5.9) 20 (23.8) 134 (6.9)
Mechanical ventilation required during
hospitalization, n (%)
114 (19.4) 166 (11.4) 232 (14.5) 48 (10.9) 10 (10.6) 149 (9.6) 68 (81.0) 212 (10.8)
Invasive 61 (10.4) 78 (5.4) 108 (6.8) 31 (7.0) 4 (4.3) 56 (3.6) 60 (71.4) 79 (4.0)
















Non-invasive 68 (11.5) 98 (6.8) 146 (9.1) 20 (4.5) 8 (8.5) 102 (6.6) 20 (23.8) 146 (7.5)
















Parenteral nutrition, n (%) 38 (6.5) 56 (3.9) 79 (4.9) 15 (3.4) 5 (5.3) 50 (3.2) 16 (19.0) 78 (4.0)


















Acute renal failure necessitating
renal replacement therapy, n (%)
25 (4.2) 21 (1.4) 36 (2.3) 10 (2.3) 1 (1.1) 16 (1.0) 22 (26.2) 24 (1.2)


















Septic shock, n (%) 40 (6.8) 44 (3.0) 61 (3.8) 23 (5.2) 4 (4.3) 34 (2.2) N/A N/A
Home-based care, n (%) 25 (4.2) 48 (3.3) 64 (4.0) 9 (2.0) 7 (7.4) 65 (4.2) 3 (3.6) 70 (3.6)





















































[10.0] (n = 1,978)
15.0 (13.2)
[11.0] (n = 190)
13.6 (11.5)
[11.0] (n = 319)
11.4 (10.6)
[9.0] (n = 48)
9.6 (6.4)
[7.0] (n = 212)
13.1 (8.5)
[11.0] (n = 298)
12.8 (14.0)
[9.0] (n = 201)
13.6 (11.3)
[10.0] (n = 121)
12.3 (9.6)
[9.5] (n = 278)
12.4 (9.3)
[10.0] (n = 197)
10.4 (9.4)
[7.0] (n = 114)
Admitted to ICU at
any time, n (%)
278 (13.6) 68 (35.6) 82 (22.4) 6 (12.0) 9 (4.2) 10 (3.3) 21 (10.3) 12 (9.9) 38 (13.6) 21 (10.5) 11 (9.6)
Time in ICU, days,
mean (SD) [median]
9.5 (11.7)
[5.0] (n = 244)
7.3 (8.7)
[4.0] (n = 65)
9.9 (12.5)
[7.0] (n = 75)
22.5 (31.5)
[3.5] (n = 6)
16.4 (13.1)
[9.0] (n = 9)
13.4 (12.1)
[8.0] (n = 8)
8.8 (10.1)
[4.0] (n = 15)
11.7 (9.3)
[7.0] (n = 11)
8.4 (10.6)








Fluid resuscitation 251 (12.3) 21 (11.0) 38 (10.4) 0 40 (18.6) 6 (2.0) 39 (19.2) 19 (5.7) 33 (11.8) 22 (11.0) 33 (28.9)
Vasopressors 101 (5.0) 21 (11.0) 22 (6.0) 2 (4.0) 3 (1.4) 5 (1.7) 4 (2.0) 11 (9.1) 18 (6.5) 12 (6.0) 3 (2.6)
Invasive procedures 30 (1.5) 6 (3.1) 6 (1.6) 1 (2.0) 1 (0.5) 2 (0.7) 1 (0.5) 1 (0.8) 8 (2.9) 4 (2.0) 0
Isolation required,
n (%)




280 (13.7) 32 (16.8) 69 (18.9) 5 (10.0) 5 (2.3) 33 (11.0) 23 (11.3) 14 (11.6) 38 (13.6) 41 (20.5) 20 (17.5)





[6.0] (n = 133)
9.5 (9.2)
[7.5] (n = 26)
8.5 (9.2)
[6.0] (n = 42)
47.5 (21.9)
[47.5] (n = 2)
25.3 (6.4)
[28.0] (n = 3)
11.4 (14.6)
[5.0] (n = 5)
12.0 (23.2)
[3.0] (n = 14)
9.0 (7.7)
[7.0] (n = 9)
12.2 (11.1)
[8.0] (n = 11)
8.0 (9.4)
[5.0] (n = 15)
9.8 (9.9)
[8.0] (n = 6)





[4.0] (n = 155)
2.9 (2.0)
[3.0] (n = 7)
5.3 (4.3)
[4.0] (n = 35)
5.4 (4.0)
[4.0] (n = 5)
8.0 (5.7)
[8.0] (n = 2)
6.0 (4.9)
[5.0] (n = 22)
3.4 (3.5)
[2.0] (n = 7)
7.2 (7.1)
[5.5] (n = 6)
4.3 (3.3)
[3.0] (n = 27)
6.6 (5.9)
[4.0] (n = 30)
2.7 (1.4)
[2.5] (n = 14)
Parenteral nutrition,
n (%)





[5.0] (n = 88)
7.2 (9.2)
[3.0] (n = 6)
6.4 (4.7)
[5.0] (n = 38)
51.5 (7.8)
[51.5] (n = 2)
12.5 (10.6)
[12.5] (n = 2)
7.7 (6.9)
[6.0] (n = 9)
17.8 (15.9)
[12.0] (n = 5)
14.5 (9.2)
[14.5] (n = 2)
13.7 (13.5)
[6.0] (n = 6)
8.7 (10.2)
[5.0] (n = 12)
1.8 (0.75)
































[3.0] (n = 37)
4.0 (4.5)
[2.0] (n = 8)
10.2 (15.1)
[4.0] (n = 5)
– 2.0 (−)
[2.0] (n = 1)
11.0 (−)
[11.0] (n = 1)
4.5 (2.1)
[4.5] (n = 2)
2.5 (1.7)
[2.0] (n = 4)
11.0 (13.3)
[5.0] (n = 7)
7.2 (4.1)
[8.0] (n = 6)
1.7 (0.6)
[2.0] (n = 3)
Septic shock, n (%) 84 (4.1) 15 (7.9) 22 (6.0) – 4 (1.9) 1 (0.3) 4 (2.0) 9 (7.4) 18 (6.5) 6 (3.0) 5 (4.4)
Home-based care,
n (%)
73 (3.6) 9 (4.7) 21 (5.7) 1 (2.0) 1 (0.5) 3 (1.0) 14 (6.9) 3 (2.5) 17 (6.1) 1 (0.5) 3 (2.6)






















Table 5 Duration of hospitalization and estimated associated costs in participating countries




Secondary-level hospital* Estimated cost of

























Belgium 10.0 424.70 624.60 6246.00 549.20 807.64 8076.40
France 11.0 396.00 582.40 6406.40 512.10 753.06 8283.66
Germany 9.0 401.10 589.84 5308.56 518.60 762.69 6864.21
Greece 7.0 266.20 391.42 2739.94 344.20 506.13 3542.91
Italy 11.0 337.80 496.80 5464.80 436.80 642.38 7066.18
The
Netherlands
9.0 493.40 725.58 6530.22 638.00 938.21 8443.89
Portugal 10.0 199.50 293.35 2933.50 257.90 379.31 3793.10
Spain 9.5 307.60 452.30 4296.85 397.70 584.85 5556.08
Turkey 10.0 147.00 112.88 1128.80 190.00 145.96 1459.60
United
Kingdom
7.0 311.40 576.60 4036.20 402.60 745.56 5218.92
*Secondary-level hospitals = hospitals intended primarily for treating referral cases, with bed size ranging from 200 to 800 beds.
†Tertiary-level/teaching hospitals = hospitals intended for referral cases, with a teaching component and highly specialised staff and technical equipment,
including ICU and bed size ranging from 300 to 1,500 beds.
‡Local currency is Euro for all countries except Turkey (Turkish Lira) and United Kingdom (GBP).
Costs are estimates of unit costs for 2007 and 2008 base-year values. They represent costs for public facilities in urban areas that are operating at 80% capacity.
Cost estimates represent only the ‘hotel’ component of hospital costs, excluding the costs of drugs and diagnostic tests but including costs such as personnel,
capital and food costs.
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on the definition of primary hospital (hospitals intended
primarily for treatment of simple cases), we excluded this
level of care from the analysis and looked only at second-
ary and teaching hospitals (definitions for each of which















Figure 1 Estimated cost of median length of stay for patients with CA
intended primarily for treating referral cases, with bed size ranging from 20
referral cases, with a teaching component and highly specialised staff and
1,500 beds.Based on the WHO CHOICE information, the esti-
mated costs for a hospital stay of 10.6 days ranged be-
tween US$1,197 (Turkey) and US$7,691 (the Netherlands)
in a secondary-level hospital and between US$1,547
(Turkey) and US$9,945 (the Netherlands) in a teaching
hospital. Using the specific median lengths of stay that
were found in the REACH study for each of the individualTertiary-level hospital costs
P in European hospitals. Secondary-level hospitals = hospitals
0 to 800 beds. Tertiary-level/teaching hospitals = hospitals intended for
technical equipment, including ICU and bed size ranging from 300 to
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http://www.biomedcentral.com/1471-2466/14/36countries (Table 5), the estimated costs of a hospital stay
ranged between US$1,129 in Turkey and US$6,530 in the
Netherlands in a secondary-level hospital and between US
$1,460 in Turkey and US$8,444 in the Netherlands in a
teaching hospital (Table 5 and Figure 1). These costs are
somewhat higher than those reported previously. For ex-
ample, a prospective observational study over 13 months
in 271 patients with CAP hospitalized in a tertiary hospital
in Spain found that the median total cost per patient was
€1,683 [9]. A prospective cohort study evaluating the costs
of CAP in Germany found that the median cost per
treated episode of CAP in 580 patients in a prospective
open study was US$1,333, of which US$604 were for
‘hotel’ costs and US$426 were for staff costs [2]. However,
these studies are limited by their small size and restriction
to single countries. The REACH study, conversely, fea-
tured patient data from numerous hospitals in ten different
countries, suggesting that the data produced are more rep-
resentative of Europe as a whole. An additional strength of
the present analysis was the use of WHO CHOICE cost es-
timates, which were produced using a robust method ap-
plied consistently across all countries.
As expected, initial antibiotic treatment modification
was associated with considerable increases in every
measure of resource use, including hospital stay, ICU ad-
mission, blood pressure support, mechanical ventilation
and renal replacement therapy, compared with patients
not requiring initial antibiotic treatment modification.
However, the causality of the relationships observed can-
not be determined from the available data, and it is im-
portant to note that certain variables such as parenteral
nutrition and renal failure may be influenced by under-
lying comorbidities. Modification of initial antibiotic treat-
ment was associated with an additional median length of
stay in hospital of 3.0 days compared with patients not re-
quiring initial antibiotic treatment modification. Based on
the WHO CHOICE costs outlined above, this would rep-
resent a considerable increase in costs for hospital stay of
between US$339 (Turkey) and US$2177 (the Netherlands)
for a secondary hospital and US$438 (Turkey) and US
$2815 (the Netherlands) for a tertiary hospital. Of course,
increased use of other supporting resources such as mech-
anical ventilation and renal replacement therapy will have
resulted in further increases in costs in patients requiring
initial antibiotic treatment modification.
Further support is provided by the analysis of resource
use by country, which demonstrated that higher levels of
resource use were observed in countries with higher initial
antibiotic treatment modification rates. For example, the
longest duration of hospital stay (mean 15.0 days) and the
highest rate of ICU admissions were observed in Belgium,
which had a high initial antibiotic treatment modification
rate. A possible alternative explanation for differences in
resource use between countries may be differences inhealthcare policies. Length of stay, for example, would vary
depending on the availability of continuing care outside
the hospital environment, and indeed the percentage of
patients requiring home-based care showed considerable
variation across the different countries. Additional support-
ive evidence comes from other studies, in which availability
of ICU beds and rates of admission to the ICU have been
shown to vary widely across different countries [10].
Previous studies show that the costs of ICU treatment
are higher than those of acute-ward treatment, with an
estimated mean total cost per patient per day of €791 in
Germany [11]. These additional costs arise from a num-
ber of factors, including use of specific resources such as
mechanical ventilation, which had a mean incremental
cost in a US study of US$1,522 per day [12]. In our
study, higher rates of admission to the ICU were ob-
served in patients with initial antibiotic treatment modi-
fication (18.0%) than in those without (11.9%) and in the
small subpopulation of patients with recurrent infection
(20.2%) than in those without (11.4%).
Considerably higher rates of ICU admission were ob-
served in patients with septic shock (82.1%) than in
those without (10.7%). Previous research has shown that
complications such as septic shock result in increased costs
because of an increased need for diagnostic procedures
and monitoring, and for further therapeutic interventions
[11]. Indeed, higher rates of mechanical ventilation, as well
as blood pressure support, parenteral nutrition and renal
replacement therapy, in patients with septic shock versus
those without were observed in the present study, confirm-
ing these prior results.
Underlying disease characteristics also have a role in
determining the level of resource use and associated
costs. For example, requirements for resource use in pa-
tients with HCAP were different to those in patients
with CAP. These results align with those of a previous,
comprehensive epidemiological study in the US, which
found that mean hospital costs were higher for patients
with HCAP than patients with CAP [13].
A key limitation of this analysis is that no cost informa-
tion was obtained directly from the hospitals enrolled in
the study, meaning that any conclusions from a health
economic perspective will need careful verification across
different health settings. Data on costs of antibiotic treat-
ment would have been interesting. Costs from hospitals in
each country may form the basis of further local analyses,
which will clarify the relevance of the findings to separate
countries and aid understanding of inter-country differ-
ences. Low patient numbers were enrolled in certain
countries, such as Germany (n = 50), the UK (n = 114) and
Portugal (n = 121), reducing the statistical value of ana-
lyses in those countries.
The REACH study has highlighted a considerable rate
of initial antibiotic treatment modification in patients
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http://www.biomedcentral.com/1471-2466/14/36hospitalized with CAP in Europe [7]. Here we have
shown that hospital resource use is high in patients with
CAP and that initial antibiotic treatment modification is
associated with higher levels of resource use, and associ-
ated costs, than are seen in patients without initial anti-
biotic treatment modification. While the causality of the
association between initial antibiotic treatment modifica-
tion and resource use cannot be determined from the
available data, these results suggest that consideration of
the influence of initial treatment choices on resource use
may be warranted.Additional file
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